Dr. Christos Karapetis
Claim this profileFlinders Medical Centre
Studies Non-Small Cell Lung Cancer
Studies Tumors
7 reported clinical trials
12 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
metastatic
locally advanced
Stage IV
2Tumors
Stage IV
Stage III
ALK positive
Clinical Trials Christos Karapetis is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Christos Karapetis
Clinical Trial Related6 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christos Karapetis has experience with
- Pembrolizumab
- Pemetrexed
- Fruquintinib
- Placebo
- Tomivosertib
- Repotrectinib (TPX-0005)
Breakdown of trials Christos Karapetis has run
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christos Karapetis specialize in?
Christos Karapetis focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved metastatic patients, or patients who are locally advanced.
Is Christos Karapetis currently recruiting for clinical trials?
Yes, Christos Karapetis is currently recruiting for 2 clinical trials in Adelaide South Australia. If you're interested in participating, you should apply.
Are there any treatments that Christos Karapetis has studied deeply?
Yes, Christos Karapetis has studied treatments such as Pembrolizumab, Pemetrexed, Fruquintinib.
What is the best way to schedule an appointment with Christos Karapetis?
Apply for one of the trials that Christos Karapetis is conducting.
What is the office address of Christos Karapetis?
The office of Christos Karapetis is located at: Flinders Medical Centre, Adelaide, South Australia 5042 Australia. This is the address for their practice at the Flinders Medical Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.